PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
Rhea-AI Summary
ProPhase Labs Inc. (NASDAQ: PRPH) has announced that it will present its second quarter 2024 financial results on August 14, 2024, at 11:00 am EDT through a virtual conference call hosted by Renmark Financial. The company will issue a press release detailing the results prior to the call. Stakeholders, investors, and other interested parties are invited to register and attend this live event. A replay of the call will be available on the company's investor website after the event. To ensure smooth connectivity, participants are advised to use the latest version of Google Chrome when accessing the registration link.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRPH declined 5.49%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company’s Investor website.
REGISTER HERE: https://www.renmarkfinancial.com/events/second-quarter-2024-results-virtual-conference-call-nasdaq-prph-l4Vthap3cH
- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About ProPhase Labs
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.
For more information, visit www.ProPhaseLabs.com.
ProPhase Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
ProPhase Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
FAQ
When will ProPhase Labs (PRPH) release its Q2 2024 financial results?
How can investors participate in ProPhase Labs' (PRPH) Q2 2024 earnings call?
Will there be a replay available for ProPhase Labs' (PRPH) Q2 2024 earnings call?
What browser is recommended for attending ProPhase Labs' (PRPH) virtual conference call?
